The Latest Breaking News from Quest Diagnostics

Quest Diagnostics Inc (NYSE:DGX) posted a better-than-expected Q1 FY22 adjusted EPS of $3.22, down 14.4% Y/Y, beating the consensus of $2.97. Sales came in at $2.61 billion, a decline of 4% Y/Y, slightly lower than the Wall Street estimate of $2.63 billion. COVID-19 testing revenues fell 27.6% to $599 million, while Base…

  Quest Diagnostics (NYSE:DGX) reported its Q1 earnings results on Thursday, April 21, 2022 at 06:45 AM. Here's what investors need to know about the announcement.

Overall positivity rate last year were up around 31% from all-time lows between 2010 and 2012.

Government funding cuts to key pandemic programs forced by GOP opposition arrive as progressives in Congress renew their push for Medicare for All.

The Centers for Disease Control and Prevention (CDC) has granted a contract to Quest Diagnostics Inc (NYSE:DGX) to perform testing and provide laboratory data analysis to help identify patterns in SARS-COV-2 seroprevalence on a multistate basis.  Quest was awarded the contract following a competitive bid. The total contract value with all options is valued…

If history is any guide, there may be trouble ahead for shares of Quest Diagnostics (NYSE:DGX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Treinta y siete estados ahora le permiten a los adultos consumir marihuana con fines médicos, recreativos o ambos. Pero, en la mayoría de esos estados, las personas pueden ser despedidas o se les puede negar un trabajo si consumen cannabis en su tiempo libre.

Thirty-seven states now allow adults to use marijuana medically, recreationally or both. But in most of those states, people can be fired or denied a job for using cannabis in their free time.

Analysts have provided the following ratings for Quest Diagnostics (NYSE:DGX) within the last quarter: